NRSN
NeuroSense Therapeutics Ltd

3,608
Mkt Cap
$28.48M
Volume
87,238.00
52W High
$2.60
52W Low
$0.6801
PE Ratio
-1.64
NRSN Fundamentals
Price
$0.93
Prev Close
$0.959
Open
$0.95
50D MA
$0.9676
Beta
0.68
Avg. Volume
347,602.86
EPS (Annual)
-$0.5489
P/B
8.62
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease PR Newswire CAMBRIDGE, Mass., Jan. 21, 2026 Patent protection...
PR Newswire·5d ago
News Placeholder
More News
News Placeholder
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB PR Newswire CAMBRIDGE, Mass., Jan. 8, 2026...
PR Newswire·18d ago
News Placeholder
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study PR...
PR Newswire·1mo ago
News Placeholder
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026 NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026 PR Newswire CAMBRIDGE, Mass., Dec. 4, 2025 CAMBRIDGE, Mass...
PR Newswire·2mo ago
News Placeholder
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS PR Newswire CAMBRIDGE...
PR Newswire·2mo ago
<
...
1
>

Latest NRSN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.